Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.08

+0.9%

Dec 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	8/14/2003 6:30:35 PM
From: Graham Marshman	Read Replies (1) of 52153

Anyone have a guesstimate on valuation range for this company: innerwebcity.com Summary: Gentic biotech. Two Phase 1 trials in progress, 14 patents. No financial info available. It's private but just yesterday "merged" with a nearly dead public company - essentially a backdoor IPO. Symbol CTPI. At the existing stock price of $.05 and float of 109M shares it currently has a market cap of $6M. Sounds like a deal to me. Snippet from news: "Change Technology Partners, Inc. (OTCBB:CTPI) today announced the signing of a definitive agreement to merge with Neurologix, Inc., a privately-held corporation. Neurologix is a leader in the development of proprietary gene therapies for the treatment of central nervous system disorders. The company was established in 1999 to commercialize therapeutic discoveries of the scientific founders, who have spent the past decade developing leading-edge technology in university settings. Neurologix's scientific founders recently became the first and only team to receive approval from the U.S. Food and Drug Administration (FDA) to conduct Phase I human clinical trials of gene therapy for the treatment of Parkinson's disease. Patients are currently being recruited for the trial, which is expected to commence later this month. Neurologix owns or licenses 14 patents and patent applications in this field, several of which support the treatment to be used in this clinical trial. Neurologix shareholders include Palisade Private Partnership, L.P." Any input appreciated, Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next